Moderna, Inc. (NASDAQ:MRNA - Get Free Report)'s stock price dropped 3.8% during mid-day trading on Monday . The company traded as low as $25.62 and last traded at $25.65. Approximately 4,655,272 shares changed hands during trading, a decline of 45% from the average daily volume of 8,393,897 shares. The stock had previously closed at $26.67.
Analyst Ratings Changes
MRNA has been the topic of a number of research reports. UBS Group dropped their price target on shares of Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Royal Bank of Canada reduced their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Evercore ISI dropped their price objective on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Finally, Citigroup assumed coverage on shares of Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 target price for the company. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average price target of $46.61.
Check Out Our Latest Report on Moderna
Moderna Stock Down 2.5%
The firm has a market cap of $10.06 billion, a P/E ratio of -2.80 and a beta of 1.86. The stock's 50-day moving average is $26.29 and its 200-day moving average is $32.91.
Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The company had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. During the same quarter in the previous year, the firm posted ($3.07) EPS. The business's revenue was down 35.3% compared to the same quarter last year. As a group, analysts expect that Moderna, Inc. will post -9.61 EPS for the current fiscal year.
Institutional Trading of Moderna
Several institutional investors have recently modified their holdings of the company. Strs Ohio bought a new position in Moderna in the first quarter worth $2,049,000. Acadian Asset Management LLC boosted its position in shares of Moderna by 313.2% during the 1st quarter. Acadian Asset Management LLC now owns 167,499 shares of the company's stock valued at $4,745,000 after acquiring an additional 126,961 shares in the last quarter. Belpointe Asset Management LLC bought a new stake in Moderna in the first quarter valued at about $232,000. Fortis Capital Advisors LLC acquired a new position in Moderna in the first quarter worth about $232,000. Finally, Focus Partners Wealth lifted its stake in Moderna by 58.7% during the first quarter. Focus Partners Wealth now owns 23,547 shares of the company's stock worth $668,000 after purchasing an additional 8,706 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.
About Moderna
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
